XDH and hyperuricemia: Recent studies have found shown that febuxostat, a non-purine selective inhibitor of xanthine oxidase (XO), is more effective and had a better safety outcome than allopurinol in lowering the uric acid levels in patients with hyperuricemia and gout (Konishi et al., 2022; Gao et al., 2021; Dehlin et al., 2020; Tsai et al., 2023).